Please login to the form below
Sanofi Pasteur
This page shows the latest Sanofi Pasteur news and features for those working in and with pharma, biotech and healthcare.
Translate Bio, Sanofi's COVID-19 vaccine proves promising in animal studies
The US-based biotech signed a deal with Sanofi in March to jointly develop a novel mRNA-based vaccine for COVID-19. ... said Thomas Triomphe, executive vice president at Sanofi Pasteur.
Latest news
-
US Department of Health and Human Services calls for coronavirus product proposals
BARDA has also partnered with French drugmaker Sanofi Pasteur’s vaccines division on a project for the novel coronavirus, which will tap into the company’s earlier work on the SARS ... virus. Sanofi’s prior work on SARS – another type of
-
Doctors worried NHS is unprepared for coronavirus as government unveils action plan
A number of pharma companies are currently undertaking research into possible vaccine candidates, including Sanofi, GlaxoSmithKline, Moderna and Gilead, among others. ... We think there are good tools and approaches at hand that will find success, but we
-
US backs Sanofi’s ‘fast-track’ coronavirus vaccine
The French drugmaker’s Sanofi Pasteur vaccines division will part with the US Biomedical Advanced Research and Development Authority (BARDA) – which is also working with other vaccine producers including Johnson &Johnson – ... By expanding our
-
HIV vaccine based on Sanofi/GSK components fails trial
The vaccine regimen is based on a canarypox vector-based vaccine called ALVAC-HIV from Sanofi Pasteur and a two-component gp120 protein subunit vaccine supplied by GlaxoSmithKline.
-
J&J pledges $500m investment into HIV and tuberculosis R&D
Another experimental study – called HVTN 702 – is testing a vaccine regimen of the ‘Thai combination’ of Sanofi Pasteur’s ALVAC-HIV and GlaxoSmithKline’s bivalent gp120/MF59.
More from news
Approximately 13 fully matching, plus 140 partially matching documents found.
Latest Intelligence
-
Deal Watch March 2017
In particular the largest deal this month, between MedImmune and Sanofi Pasteur, has a headline figure of $650m, a figure which would have had the deal struggling to get into the ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur. Joint Development.
-
Going fully digital
Sanofi Pasteur MSD previously required upwards of nine months to bring approved commercial content to market in many of its largest markets. ... Sanofi Pasteur MSD also projects overall efficiency gains of 17% in year one and 33% annually in years two
-
Deal Watch table for July 2014
preclinical). 225. CureVac/ Sanofi Pasteur. Exercise of option, licence. RNActive vaccine technology vs undisclosed pathogens (preclinical).
-
Pharma deals during July 2014
Scandinavia. CureVac's relationship with Sanofi Pasteur dates back to 2011 when the companies entered into a collaboration and option agreement covering mRNA-based vaccines generated using CureVac's RNActive technology ... Sanofi Pasteur has now
-
Deal Watch table for March 2014
26.6. ‡SK Chemicals/ Sanofi Pasteur. Collaboration. Pneumococcal conjugate vaccine (PCV). 23. ... Japan . Outside US, Canada. ‡ Sanofi Pasteur has rights outside Korea; SK has exclusive rights for Korea.
More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.
Latest appointments
-
Dominique Carouge joins Sanofi as head of business transformation
Carouge, who also becomes a member of Sanofi’s executive committee, will be at the helm of accelerating the transformation of the company. ... for Sanofi Pasteur since 2009.
-
STEM Healthcare bolsters its EU5 team
Meanwhile, Joanna Troman (pictured left) moves to STEM as a project director following 10 years as Sanofi Pasteur MSD in a number of roles across marketing, strategic planning and market research.
-
Hanover Brussels appoints Aurélie Marchand as account director
Prior to Hill &Knowlton, Marchand served Sanofi, where she worked on French Parliament relations and she has held several positions within the French administration working for general secretariat for European affairs ... In her new role, Marchand will
-
Cello Health Consulting expands its UK team
Tarplee has over 30 years of life science industry experience and previously worked for the likes of Adherium, ALK Abello, Sanofi and Abbott. ... Lim previously worked at Novartis and Sanofi Pasteur, and most recently served at Takeda Pharmaceuticals as
-
Dean Sowman joins Portland Health
He joins Portland from MHP Communications, where his two-year stint saw him rise to a senior account manager role and included a secondment to Sanofi Pasteur MSD’s comms team.
More from appointments
Approximately 1 fully matching, plus 16 partially matching documents found.
Latest from PMHub
-
emotive boosts health economics and outcomes research team
Sam previously held positions at Monitor and Sanofi Pasteur MSD (Merck Sharp &Dohme).
-
Happy New Year from an expanding emotive team
Adam Goodband joined emotive as a Strategic Planner in January 2014, having previously worked as a Medical Writer at Sanofi Pasteur MSD, has been promoted to Senior Strategic Planner.
-
Adam Goodband joins emotive as a Strategic Planner
emotive are pleased to announce the addition of former Sanofi Pasteur MSD medical writer to the team. ... Having experienced working alongside emotive as a medical writer for Sanofi Pasteur MSD, Adam was keen to join the team and bring his skills and
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How COVID-19 is accelerating the threat of antimicrobial resistance
- Lilly’s Verzenio scores a win in early-stage breast cancer
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
- FDA hands BMS and bluebird bio a priority review for ide-cel
- FDA approves Roche’s Actemra COVID-19 trial
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
PMHub
Research Partnership
We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
